Statement on agenda Item: 12.5
Global Action on Patient Safety

Quality of care and patient safety are interlinked. And, to achieve it, public health systems need to be strengthened, public financing increased and the private health sector needs to be well regulated and controlled.

In 2015, the WHO published standards on clinical trials, stating that the registration and reporting of all trials within 12 months of completion was a "scientific, ethical, and moral responsibility". Clinical trial data suppression distorts evidence, wastes research funds and harms patients by hiding adverse effects. It contradicts the principles of the Helsinki declaration.

Clinical trials that focus on the development of medical products and devices must take into account patient safety through the conception, implementation, monitoring, and evaluation of the study. This can be accomplished by assessing hazards and mitigating hazards during the study to protect the patient and to ‘do no harm’.

We urge MS to support this resolution and provide adequate funding to WHO for it’s implementation. We urge WHO and MS to consider the intersection of patient safety and quality of care when implementing this resolution. MS need to work together to ensure when patients access health services, they receive quality and safe care.

Total: 192 words

Statement to be read by: Alane Ribeiro

Contact (phone, e-mail): alane.andrelino@gmail.com